Keros Therapeutics (KROS) Current Assets (2019 - 2025)

Keros Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $315.4 million for Q4 2025.

• Quarterly Current Assets fell 46.44% year-over-year to $315.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $315.4 million (down 46.44% YoY) and the FY2025 annual result came in at $315.4 million, down 46.44% from the prior year.
• Current Assets was $315.4 million for Q4 2025 at Keros Therapeutics, down from $719.3 million in the prior quarter.
• Across five years, Current Assets topped out at $759.5 million in Q1 2025 and bottomed at $222.4 million in Q2 2022.
• A 5-year average of $393.6 million and a median of $324.9 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2021 — Current Assets jumped 337.28% — and 2025, when it sank 46.44%.
• Keros Therapeutics' Current Assets stood at $251.4 million in 2021, then climbed by 13.65% to $285.8 million in 2022, then rose by 21.53% to $347.3 million in 2023, then surged by 69.57% to $588.9 million in 2024, then sank by 46.44% to $315.4 million in 2025.
• Business Quant data shows KROS's Current Assets at $315.4 million in Q4 2025, $719.3 million in Q3 2025, and $732.8 million in Q2 2025.